DV 7028

selective 5-HT2 receptor antagonist

Also Known As:

3-(2-(4-(4-fluorobenzoyl)piperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-2H-pyrido(1,2-a)-1,3,5-triazine-2,4(3H)dione maleate; DV-7028; 2H-Pyrido(1,2-a)-1,3,5-triazine-2,4(3H)-dione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-, (Z)-2-butenedioate (1:1)

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Triazines: 306
    - DV 7028: 7
  - Piperidines: 17
    - DV 7028: 7

Related Diseases

1.	Coronary Stenosis (Coronary Artery Stenosis) 07/01/1993 - "The combined regimen of DV-7028 and aspirin or heparin in treatment of acute coronary stenosis is more effective than that of aspirin or heparin alone."
2.	Thrombosis (Thrombus) 06/15/1998 - "A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats." 09/01/1991 - "The effects of intravenous DV-7028, a selective 5-HT2 receptor antagonist (bolus of 0.1 mg.kg-1, followed by 0.3 mg.kg-1.h-1 by infusion), and intravenous aspirin (1 mg.kg-1, followed by 3 mg.kg-1.h-1) in this experimental thrombus model were examined. " 09/01/1991 - "The results suggest that 5-HT is involved in the platelet thrombosis and that inhibitory effect of DV-7028, a 5-HT2 receptor antagonist, on coronary thrombus formation was superior to that of aspirin." 06/15/1998 - "In our study, we demonstrated that DV-7028: (3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6, 7,8,9-tetrahydro-2H-pyrido [1,2,-a]-1,3,5-triazine-2, 4(3H)-dione maleate)--a selective 5-HT2A receptor antagonist, inhibited thrombus formation in the arterial thrombosis model and was completely ineffective in the prevention of venous thrombosis in the rat. "
3.	Venous Thrombosis (Deep-Vein Thrombosis) 06/15/1998 - "The present data demonstrate that DV-7028 exhibits 5-HT2A receptor antagonistic properties in the rat cardiovascular system, exhibits antithrombotic effect in the model of arterial but not venous thrombosis in rats. " 06/15/1998 - "In our study, we demonstrated that DV-7028: (3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6, 7,8,9-tetrahydro-2H-pyrido [1,2,-a]-1,3,5-triazine-2, 4(3H)-dione maleate)--a selective 5-HT2A receptor antagonist, inhibited thrombus formation in the arterial thrombosis model and was completely ineffective in the prevention of venous thrombosis in the rat. "
4.	Right Ventricular Hypertrophy 09/01/1993 - "Administration of DV-7028 (20 mg.kg-1 x d-1) attenuated the increase in pulmonary arterial pressure, right ventricular hypertrophy, and medial thickening of the pulmonary arteries. " 04/01/1994 - "Oral administration of DV-7028 (10 mg/kg, twice daily) significantly suppressed the MCT-induced elevation of pulmonary arterial pressure, right ventricular hypertrophy and medial thickening of the muscular-type pulmonary arteries which occurred 23 days after MCT administration. "
5.	Hypotension (Low Blood Pressure) 08/01/1998 - "Besides this peripheral action, DV-7028, when applied in high doses, exerts hypotension and bradycardia via an unknown site and mechanism." 08/01/1998 - "In pithed rats, bradycardia and hypotension were not demonstrated after DV-7028 administration. " 01/01/1996 - "Besides its peripheral action, DV-7028 exerts central effects which cause hypotension and bradycardia." 08/01/1998 - "In this experimental model, DV-7028 inhibited the pressor effects of serotonin at doses of 0.01 and 0.1 mg/kg, which caused neither hypotension nor bradycardia in anesthetized rats. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Heparin (Liquaemin)
3.	5-HT2A Serotonin Receptor (5 HT2A Receptor)
4.	Triazines
5.	maleic acid (maleate)
6.	Serotonin (5 Hydroxytryptamine)
7.	Serotonin Receptors

Related Therapies and Procedures

1.	Intravenous Administration
2.	Vagotomy
3.	Oral Administration